Anti-IFNα immunization raises the IFNα-neutralizing capacity of serum - An adjuvant to antiretroviral tritherapy

D. Zagury, H. Lecoq, I. Gervi, H. Le Buanec, J. F. Zagury, B. Bizzini, A. Burny, P. Hermans, M. Perja, E. Santagostino, A. Gringeri

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

HAART (highly active antiretroviral therapy) suppresses but does not eradicate HIV-1 infection. However since the antiretroviral agents used in HAART may also be toxic in the long-term, immunotherapies which correct HIV- 1 immunosuppression or the cytokine dysregulation associated with it may be beneficial. In this respect, a double blind multicentric placebo-controlled phase II/III anti-IFNα vaccine trial has been carried out on 242 HIV-1 patients, the majority of whom were undergoing HAART treatment. In vaccinated patients (vaccinees) who responded to immunization by increased levels of IFNα Abs (whether under HAART or not) when compared to placebo or non- responder vaccinees, a strong correlation was found between an increased IFNα neutralizing capacity and the reduction of clinical manifestations.

Original languageEnglish
Pages (from-to)90-92
Number of pages3
JournalBiomedicine and Pharmacotherapy
Volume53
Issue number2
DOIs
Publication statusPublished - Mar 1999

Fingerprint

Highly Active Antiretroviral Therapy
Immunization
HIV-1
Serum
Placebos
Anti-Retroviral Agents
Poisons
Immunotherapy
Immunosuppression
HIV Infections
Vaccines
Cytokines
Therapeutics

Keywords

  • Anti-IFNα vaccine
  • HAART
  • IFNα-neutralizing capacity

ASJC Scopus subject areas

  • Pharmacology

Cite this

Anti-IFNα immunization raises the IFNα-neutralizing capacity of serum - An adjuvant to antiretroviral tritherapy. / Zagury, D.; Lecoq, H.; Gervi, I.; Le Buanec, H.; Zagury, J. F.; Bizzini, B.; Burny, A.; Hermans, P.; Perja, M.; Santagostino, E.; Gringeri, A.

In: Biomedicine and Pharmacotherapy, Vol. 53, No. 2, 03.1999, p. 90-92.

Research output: Contribution to journalArticle

Zagury, D, Lecoq, H, Gervi, I, Le Buanec, H, Zagury, JF, Bizzini, B, Burny, A, Hermans, P, Perja, M, Santagostino, E & Gringeri, A 1999, 'Anti-IFNα immunization raises the IFNα-neutralizing capacity of serum - An adjuvant to antiretroviral tritherapy', Biomedicine and Pharmacotherapy, vol. 53, no. 2, pp. 90-92. https://doi.org/10.1016/S0753-3322(99)80065-1
Zagury, D. ; Lecoq, H. ; Gervi, I. ; Le Buanec, H. ; Zagury, J. F. ; Bizzini, B. ; Burny, A. ; Hermans, P. ; Perja, M. ; Santagostino, E. ; Gringeri, A. / Anti-IFNα immunization raises the IFNα-neutralizing capacity of serum - An adjuvant to antiretroviral tritherapy. In: Biomedicine and Pharmacotherapy. 1999 ; Vol. 53, No. 2. pp. 90-92.
@article{db5e2d9a8fb444798cf7ea4d35ea91d4,
title = "Anti-IFNα immunization raises the IFNα-neutralizing capacity of serum - An adjuvant to antiretroviral tritherapy",
abstract = "HAART (highly active antiretroviral therapy) suppresses but does not eradicate HIV-1 infection. However since the antiretroviral agents used in HAART may also be toxic in the long-term, immunotherapies which correct HIV- 1 immunosuppression or the cytokine dysregulation associated with it may be beneficial. In this respect, a double blind multicentric placebo-controlled phase II/III anti-IFNα vaccine trial has been carried out on 242 HIV-1 patients, the majority of whom were undergoing HAART treatment. In vaccinated patients (vaccinees) who responded to immunization by increased levels of IFNα Abs (whether under HAART or not) when compared to placebo or non- responder vaccinees, a strong correlation was found between an increased IFNα neutralizing capacity and the reduction of clinical manifestations.",
keywords = "Anti-IFNα vaccine, HAART, IFNα-neutralizing capacity",
author = "D. Zagury and H. Lecoq and I. Gervi and {Le Buanec}, H. and Zagury, {J. F.} and B. Bizzini and A. Burny and P. Hermans and M. Perja and E. Santagostino and A. Gringeri",
year = "1999",
month = "3",
doi = "10.1016/S0753-3322(99)80065-1",
language = "English",
volume = "53",
pages = "90--92",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson SAS",
number = "2",

}

TY - JOUR

T1 - Anti-IFNα immunization raises the IFNα-neutralizing capacity of serum - An adjuvant to antiretroviral tritherapy

AU - Zagury, D.

AU - Lecoq, H.

AU - Gervi, I.

AU - Le Buanec, H.

AU - Zagury, J. F.

AU - Bizzini, B.

AU - Burny, A.

AU - Hermans, P.

AU - Perja, M.

AU - Santagostino, E.

AU - Gringeri, A.

PY - 1999/3

Y1 - 1999/3

N2 - HAART (highly active antiretroviral therapy) suppresses but does not eradicate HIV-1 infection. However since the antiretroviral agents used in HAART may also be toxic in the long-term, immunotherapies which correct HIV- 1 immunosuppression or the cytokine dysregulation associated with it may be beneficial. In this respect, a double blind multicentric placebo-controlled phase II/III anti-IFNα vaccine trial has been carried out on 242 HIV-1 patients, the majority of whom were undergoing HAART treatment. In vaccinated patients (vaccinees) who responded to immunization by increased levels of IFNα Abs (whether under HAART or not) when compared to placebo or non- responder vaccinees, a strong correlation was found between an increased IFNα neutralizing capacity and the reduction of clinical manifestations.

AB - HAART (highly active antiretroviral therapy) suppresses but does not eradicate HIV-1 infection. However since the antiretroviral agents used in HAART may also be toxic in the long-term, immunotherapies which correct HIV- 1 immunosuppression or the cytokine dysregulation associated with it may be beneficial. In this respect, a double blind multicentric placebo-controlled phase II/III anti-IFNα vaccine trial has been carried out on 242 HIV-1 patients, the majority of whom were undergoing HAART treatment. In vaccinated patients (vaccinees) who responded to immunization by increased levels of IFNα Abs (whether under HAART or not) when compared to placebo or non- responder vaccinees, a strong correlation was found between an increased IFNα neutralizing capacity and the reduction of clinical manifestations.

KW - Anti-IFNα vaccine

KW - HAART

KW - IFNα-neutralizing capacity

UR - http://www.scopus.com/inward/record.url?scp=0033102085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033102085&partnerID=8YFLogxK

U2 - 10.1016/S0753-3322(99)80065-1

DO - 10.1016/S0753-3322(99)80065-1

M3 - Article

VL - 53

SP - 90

EP - 92

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 2

ER -